Alpha DNA Investment Management LLC Has $1.87 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Alpha DNA Investment Management LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,751 shares of the medical instruments supplier’s stock after acquiring an additional 165 shares during the period. Alpha DNA Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $1,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. WR Wealth Planners LLC boosted its stake in shares of Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after purchasing an additional 42 shares during the last quarter. Clear Creek Financial Management LLC raised its stake in shares of Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Central Pacific Bank Trust Division boosted its holdings in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp boosted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $224.00 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The business has a 50-day moving average price of $235.15 and a 200-day moving average price of $234.54. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $64.74 billion, a price-to-earnings ratio of 37.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.42 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.86%. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.